Roche Holding AG - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RHHBY Over the counter 2834 www.roche.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roche Holding AG

CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis - Sep 18th, 2026 4:45 am
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug - Sep 18th, 2026 4:24 am
Roche agrees to $1bn deal with Dualitas for bispecific antibody research - Sep 18th, 2026 3:29 am
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? - Sep 18th, 2026 3:04 am
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center - Sep 17th, 2026 12:30 pm
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases - Sep 17th, 2026 12:30 pm
Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma - Sep 17th, 2026 9:11 am
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study - Sep 17th, 2026 8:48 am
Roche’s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma - Sep 17th, 2026 8:25 am
Compagnie Financiere Richemont SA's Dividend Analysis - Sep 17th, 2026 5:00 am
Dualitas Therapeutics Announces Proximity Biology Research Collaboration with Roche to Discover and Develop Novel Bispecific Antibodies for I&I Diseases - Sep 17th, 2026 4:00 am
Roche, Dualitas team up to find bispecific drugs for immune diseases - Sep 17th, 2026 12:00 am
Roche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study - Sep 16th, 2026 11:00 pm
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study - Sep 16th, 2026 11:00 pm
TG Therapeutics Makes A Bullish Move Amid Ongoing Roche Rivalry - Sep 16th, 2026 2:02 pm
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? - Sep 16th, 2026 8:44 am
AstraZeneca shares oversold after trial flops and merger talk, says UBS - Sep 16th, 2026 8:37 am
Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Players - Sep 16th, 2026 3:05 am